Recent Updates
Recently added Catalysts
PRQR

ProQR to Present at Two Upcoming Investor Conferences in May

Key Takeaway: LEIDEN, the Netherlands, April 29, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), today announced that Daniel de Boer, Chief Executive Officer, will take part in a fireside chat at the Deutsche Bank 40th Annual Health Care Conference on Thursday, May 7, 2015 at 2

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+44%
120-day peak, hindsight
Typical move
6.8%
average across 3 past catalysts
Lead asset
QR-010
Phase 1 · Cystic Fibrosis

Full Press Release Details

LEIDEN, the Netherlands, April 29, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), today announced that Daniel de Boer, Chief Executive Officer, will take part in a fireside chat at the Deutsche Bank 40th Annual Health Care Conference on Thursday, May 7, 2015 at 2:50pm ET and will give a presentation about the company's CF program at the Cystic Fibrosis Workshop hosted by JMP Securities on Friday May 8, 2015 at 11:00am ET. Both conferences will be in Boston, MA, USA.
The live and archived webcast of the fireside chat at the Deutsche Bank Conference will be accessible from the "Investor Relations" section of ProQR's website (www.proqr.com). The archived webcast will be available for 30 days following the presentation date.
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Since 2012.
ProQR Therapeutics N.V.:
Last updated: Apr 29, 2015